14T110: Editor's Picks 2023: Arthritis & Rheumatology and Annals of the Rheumatic Diseases

Speaker(s)

• 

  Matthew Baker, MD, MS

  Stanford University
  Menlo Park, CA, United States

  Disclosure(s): Beigene: Grant/Research Support (Ongoing); Eli Lilly: Grant/Research Support (Ongoing); Horizon Therapeutics: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Mobility Bio: Consultant (Ongoing); Nēsos: Advisor or Review Panel Member (Terminated, October 1, 2018), Consultant (Terminated, October 1, 2018); Roivant: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Grant/Research Support (Ongoing); Zenas Biopharma: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing)
• 

  Lihi Eder, MD, PhD

  University of Toronto
  Toronto, ON, Canada

  Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Terminated, April 12, 2023); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)
• 

  Siri Lillegraven, MD, PhD, MPH

  Diakonhjemmet Hospital
  Oslo, Norway

  Disclosure(s): Boehringer-Ingelheim: Grant/Research Support (Ongoing)
• 

  Gregg Silverman, MD

  Professor, Department of Medicine
  NYU Grossman School of Medicine
  New York, NY, United States

  Disclosure(s): No financial relationships with ineligible companies to disclose
• 

  Josef Smolen, MD

  Medical University of Vienna
  Vienna, Austria

  Disclosure(s): AbbVie: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Amgen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Annals of the Rheumatic Diseases: Editor (Ongoing); AstraZeneca: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Astro: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Celgene: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Celltrion: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Chugai: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Eli Lilly: Grant/Research Support (Ongoing); EULAR Task Forces and T2T Task Forces: Convenor (Ongoing); Gilead: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); ILTOO: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Janssen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Lilly: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Merck Sharp & Dohme: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Grant/Research Support (Ongoing); Novartis-Sandoz: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Rheumatology 7E/8E: Co-editor (Ongoing); Roche: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); R-Pharma: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Samsung: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sanofi: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); UCB Pharma: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
• 

  Daniel Solomon, MD, MPH

  Brigham and Women's Hospital
  Newton, MA, United States

  Disclosure(s): Janssen: Grant/Research Support (Ongoing)

The session will provide the audience with early view of four accepted papers at Arthritis & Rheumatology and the Annals of Rheumatic Diseases, two from each journal that are in press. In addition to hearing cutting edge science, the audience will better appreciate what types of studies both premier journals look to publish. The Editors-in-Chief will discuss the article selection process, describe current issues facing rheumatology journals, and answer questions about the editorial process.

Presentations:

• 7:30 AM – 7:35 AM PT

  Introduction
  

  Speaker: Josef Smolen, MD – Medical University of Vienna
• 7:35 AM – 7:45 AM PT

  A Randomized Double-blind Sham-controlled Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis
  

  Speaker: Matthew Baker, MD, MS – Stanford University
• 7:45 AM – 7:50 AM PT

  Q&A
  
• 7:50 AM – 8:00 AM PT

  Effect of Tapered Versus Stable Treatment with Tumor Necrosis Factor Inhibitors on Disease Flares in Patients with Rheumatoid Arthritis in Remission: A Randomized, Open-Label, Non-Inferiority Trial
  

  Speaker: Siri Lillegraven, MD, PhD, MPH – Diakonhjemmet Hospital
• 8:00 AM – 8:05 AM PT

  Q&A
  
• 8:05 AM – 8:15 AM PT

  Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (PRESTO): A Step Towards Prevention
  

  Speaker: Lihi Eder, MD, PhD – University of Toronto
• 8:15 AM – 8:20 AM PT

  Q&A
  
• 8:20 AM – 8:25 AM PT

  Longitudinal Gut Microbiome Analyses and Blooms of Pathogenic Strains during Lupus Disease Flares
  

  Speaker: Gregg Silverman, MD – NYU Grossman School of Medicine
• 8:25 AM – 8:35 AM PT

  Q&A
  
• 8:35 AM – 8:40 AM PT

  Summary
  

  Speaker: Daniel H. Solomon, MD, MPH – Brigham and Women's Hospital
• 8:40 AM – 9:00 AM PT

  Open Q&A